For instance, participants who were fully immunized with the Moderna mRNA-1273 COVID-19 vaccine have sera that demonstrates neutralizing activity against the SARS-CoV-2 variants: the Alpha variant (B.1.1.7), the Beta variant (B.1.351-v1, B.1.351-v2, and B.1.351-v3), the Delta variant (B.1.617.2), and the Gamma variant (P.1) (22). dose with a gradual decline of antibody levels at later time. Anti-nucleocapsid antibody was not induced by spike protein-encoding vaccines and this may continue to serve as a marker of previous SARS-CoV-2 contamination. No differences between the two vaccines in terms of antibody response were revealed. Age and gender dependencies were determined to be minimal within the healthy adult (but not aged) populace. Rubusoside Our results suggest that postvaccination testing of antibody response is an important and feasible tool for following people after vaccination and selecting individuals who might require a third dose of vaccine at an earlier time point or persons who may not need a second dose due to previous SARS-CoV-2 infection. IMPORTANCENow that authorized vaccines for COVID-19 have been widely used, Rubusoside it is important to understand how they induce antivirus antibodies, which antigens are targeted, how long antibodies circulate, and how personal health conditions and age may affect this humoral immunity. Here, we report induction and time course of multiple anti-SARS-CoV-2 antibody responses in healthy individuals immunized with Pfizer and Moderna mRNA vaccines. We also decided the age and gender dependence of the antibody response and compared antibody levels to responses seen in those who have recovered from COVID-19. Our results suggest the importance of screening for antibody response to multiple antigens after vaccination in order to reveal individuals who require early and late additional boosting and those who may not need second dose due to prior SARS-CoV-2 contamination. KEYWORDS:antibody, COVID-19, SARS-CoV-2, vaccination, humoral immunity == INTRODUCTION == Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, is usually a single-stranded RNA computer virus which can be exceeded between humans and is the Rubusoside cause of the coronavirus pandemic, which began in 2019. Contamination with SARS-CoV-2 may result in coronavirus disease 2019 (COVID-19), which commonly induces a strong and persistent immune response to SARS-CoV-2. This includes virus-specific antibodies, memory B FCRL5 cells, and effector and memory CD8+T cells (1,2). The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) Rubusoside for the first two SARS-CoV-2 vaccines in December 2020the Pfizer-BioNTech and Moderna vaccinesfor the prevention of COVID-19 in the United States and the protection of persons who are at high risk for complications (3,4). Both vaccines use nucleoside-modified mRNA with a lipid nanoparticle-formulation to encode the spike (S) protein of SARS-CoV-2. It is considered crucial that SARS-CoV-2 vaccines provoke a strong immune response against the spike protein, particularly the receptor-binding domain name (RBD) of the spike protein which contains many neutralizing epitopes (5). Therefore, many vaccines utilize stabilizing mutations in the S glycoprotein to maintain the prefusion conformation and prevent shedding of the S1 subunit (6). Available information to date seems to indicate that these mutated S proteins are more immunogenic than the wild-type S protein. Both the mRNA-1273 vaccine (Moderna) and the BNT162b2 vaccine (Pfizer) (7) encode the full-length viral S ectodomain with a transmembrane anchor and two S-2P mutations which serve to stabilize the prefusion conformation (7,8). Initially, Pfizer clinically investigated the BNT162b1 vaccine candidate that incorporates altered mRNA to encode only the RBD portion of the S protein, thought to be the key target of virus-neutralizing antibodies (9). The RBD antigen that resulted from BNT162b1 had an additional T4 fibritin-derived fold in the trimerization domain name which served to increase immunogenicity (10). Later, Pfizer reported that this BNT162b2, which encoded the full-length stabilized S glycoprotein, elicited dose-dependent SARS-CoV-2 neutralizing antibody titers comparable or higher than those elicited by a defined panel of convalescent SARS-CoV-2 serum samples (11). The full-length protein vaccine was shown to have fewer side effects and Rubusoside was better tolerated than other vaccine candidates. Using the full-length glycoprotein vaccine, a randomized, placebo-controlled trial was performed with over 40,000 participants. The trial found that two doses of BNT162b2 exhibited 95% protection against COVID-19 (7). The Moderna mRNA-1273 vaccine encodes the S-2P antigen (15-1208; a mutant recombinant version of the S glycoprotein with proline replacements at amino acids 986 and 987) (12,13),.